Perhaps the most compelling evidence for the importance of unmutated oncogenic driver proteins in SCCs is the approval and widespread use of the chimeric anti-EGFR antibody cetuximab as a standard of care treatment for HNSCC [53,54]. Here, EGFR is linked to head and neck squamous cell carcinoma.